

The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books

Feb 9, 2021 • 1h 9min
Ep86: Sek Kathiresan on a Gene-Edited Single Shot for Heart Disease
Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, on a gene edited single shot for cardiovascular disease.

Jan 20, 2021 • 47min
Ep85: Luhan Yang on CRISPR Editing for Organ Transplants
Luhan Yang, CEO of Qihan Bio, on CRISPR editing for organ transplants.

Dec 22, 2020 • 1h 9min
Ep84: Steve Paul on Treatments for Mental Health
Steve Paul, CEO of Karuna Therapeutics, on neuropsychiatric drug development.

Dec 14, 2020 • 58min
Ep83: David Lee on Impact in Pharmaceuticals
David Lee, CEO of Servier Pharma, on a nonprofit model.

Nov 23, 2020 • 59min
Ep82: Andrew Farnum on Medicines From Unusual Traits
Andrew Farnum, CEO of Variant Bio, on drug discovery based on rare genetic traits.

Nov 12, 2020 • 1h 7min
Ep81: Simba Gill on Microbiome Therapies
Simba Gill, CEO of Evelo Biosciences, on microbiome therapies.

Oct 28, 2020 • 52min
Ep80: Peter Kolchinsky on Pharma's Soul
Peter Kolchinsky of RA Capital on making drugs affordable, and keeping incentives for drug discovery.

Oct 26, 2020 • 1h 10min
Ep79: Daphne Koller on Machine Learning for Drug Discovery
Daphne Koller, CEO of insitro, on machine learning for drug discovery

Oct 13, 2020 • 1h 6min
Ep78: Pearl Huang on Exoneural Cancer Biology
Pearl Huang, CEO of Cygnal Therapeutics, on Exoneural Cancer Biology

Sep 29, 2020 • 1h 21min
Ep77: Jennifer Petter on Drugging RNA Targets
Jennifer Petter, CSO of Arrakis Therapeutics, on small molecule drugs for RNA targets